Resting energy use in kids with inflammatory bowel disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This national, multicenter, prospective observational study measures resting energy expenditure (REE) in pediatric patients with new inflammatory bowel disease using indirect calorimetry and compares it with predictive equations. Researchers will collect clinical, laboratory, anthropometric, nutritional, and disease activity data at diagnosis, after induction therapy, and during follow-up to explore links between REE, disease activity, and treatment. The study aims to better understand nutritional needs in pediatric IBD and inform individualized nutritional support. No pharmacologic intervention is involved; the study observes standard care data and REE measurements.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Pediatric patients aged 6 to 17 years
* New diagnosis of inflammatory bowel disease, including Crohn disease or ulcerative colitis, according to ECCO/ESPGHAN criteria
* Written informed consent signed by parents or legal guardians

Exclusion Criteria:

* Intestinal surgery within 6 weeks before the first evaluation
* Parenteral or enteral nutrition within 6 weeks before the first evaluation
* Eating disorders or other chronic diseases associated with possible malabsorption

Where it's running

• Pediatric Unit
  Alessandria, Piedmont, Italy Recruiting

Study contacts

• Study coordinator: Clinical Trial Center (CTC)
• Email: clinicaltrialcenter@ospedale.al.it
• Phone: 0131206893

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Intestinal ultrasound-guided management for inflammatory bowel disease

  This study tests if adding point-of-care intestinal ultrasound at every visit changes treatment decisions for adults with Crohn’s disease or ulcerative colitis undergoing disease assessment.

  Recruiting Mahidol University · Bangkok · NCT07775352

• Long-acting antibody treatments alone and in combinations for moderate to severe ulcerative colitis

  This tests long-acting antibody medicines, given after an IV induction and then as under-the-skin maintenance, to see if they help adults with moderate to severe ulcerative colitis.

  Recruiting at 276 sites Phase 2 Spyre Therapeutics, Inc. · Canoga Park, California and 275 other locations · NCT07012395

• Examining the link between polyamine levels and inflammatory bowel disease progression

  This study is trying to see if measuring certain substances in the body can help predict how inflammatory bowel diseases like Ulcerative Colitis and Crohn's Disease will progress in patients.

  Recruiting Xijing Hospital · Xi'an, Shaanxi · NCT06995170

• Using advanced imaging to assess inflammation in bowel diseases

  This study is testing if a new imaging technique can help doctors better see inflammation in patients with Inflammatory Bowel Disease compared to the standard method.

  Recruiting University of Ulm · Ulm, Baden-Wurttemberg · NCT06892990

• Evaluating inflammation in children with inflammatory bowel disease

  This study is testing a new device to see how it can help doctors understand inflammation in children with Crohn's disease and ulcerative colitis, so they can provide better treatment.

  Recruiting Children's National Research Institute · Washington D.C., District of Columbia · NCT06065228

• Long-Term Guselkumab Use in Adults with Inflammatory Bowel Disease

  This study looks at how long adults with Crohn's disease or ulcerative colitis stay on guselkumab in real-world care.

  Recruiting Janssen Research & Development, LLC · Amiens · NCT07822529

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.